Dermira Inc (NASDAQ:DERM)’s stock price dropped 6.9% during trading on Thursday . The stock traded as low as $7.51 and last traded at $7.53, approximately 906,800 shares traded hands during mid-day trading. A decline of 26% from the average daily volume of 1,230,418 shares. The stock had previously closed at $8.09.
A number of brokerages have recently issued reports on DERM. BidaskClub raised shares of Dermira from a “strong sell” rating to a “sell” rating in a research report on Saturday, October 19th. Zacks Investment Research raised shares of Dermira from a “hold” rating to a “strong-buy” rating and set a $6.50 price objective on the stock in a research report on Wednesday, October 9th. Needham & Company LLC reaffirmed a “buy” rating and issued a $22.00 price objective on shares of Dermira in a research report on Friday, October 18th. Finally, Leerink Swann cut their price objective on shares of Dermira from $23.00 to $15.00 and set an “outperform” rating on the stock in a research report on Tuesday, November 5th. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company’s stock. Dermira currently has an average rating of “Buy” and a consensus target price of $17.12.
The business’s 50-day moving average price is $6.66 and its 200-day moving average price is $8.52. The company has a current ratio of 7.03, a quick ratio of 6.63 and a debt-to-equity ratio of 25.08. The stock has a market cap of $438.62 million, a PE ratio of -1.44 and a beta of 1.33.
In other Dermira news, Director Matthew K. Fust sold 6,000 shares of the business’s stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $8.77, for a total transaction of $52,620.00. Following the sale, the director now owns 11,051 shares of the company’s stock, valued at approximately $96,917.27. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO Thomas G. Wiggans bought 23,419 shares of the company’s stock in a transaction on Monday, August 19th. The shares were bought at an average cost of $8.54 per share, for a total transaction of $199,998.26. Following the transaction, the chief executive officer now owns 39,666 shares in the company, valued at approximately $338,747.64. The disclosure for this purchase can be found here. 12.40% of the stock is owned by insiders.
Large investors have recently added to or reduced their stakes in the business. Point72 Hong Kong Ltd grew its position in Dermira by 124.2% during the 2nd quarter. Point72 Hong Kong Ltd now owns 4,170 shares of the biopharmaceutical company’s stock worth $40,000 after purchasing an additional 2,310 shares during the last quarter. Bank of Montreal Can grew its position in Dermira by 621.8% during the 2nd quarter. Bank of Montreal Can now owns 4,533 shares of the biopharmaceutical company’s stock worth $43,000 after purchasing an additional 3,905 shares during the last quarter. Advisor Group Inc. grew its position in Dermira by 41.7% during the 2nd quarter. Advisor Group Inc. now owns 8,589 shares of the biopharmaceutical company’s stock worth $83,000 after purchasing an additional 2,527 shares during the last quarter. Atria Investments LLC purchased a new stake in Dermira during the 2nd quarter worth approximately $85,000. Finally, Fox Run Management L.L.C. purchased a new stake in Dermira during the 2nd quarter worth approximately $120,000. 94.44% of the stock is currently owned by institutional investors.
Dermira Company Profile (NASDAQ:DERM)
Dermira, Inc, a biopharmaceutical company, develops and commercializes therapies for patients with dermatologic diseases in the United States. The company offers QBREXZA, a topical once-daily anticholinergic cloth for the treatment of primary axillary hyperhidrosis in adult and pediatric patients nine years of age and older.
Recommended Story: Why is the LIBOR significant?
Receive News & Ratings for Dermira Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira and related companies with MarketBeat.com's FREE daily email newsletter.